Literature DB >> 3780114

Steady-state carbamazepine plasma concentration-dose ratios in epileptic patients.

A Sánchez, J A Durán, J S Serrano.   

Abstract

The distribution of carbamazepine plasma concentration-dose ratio was studied in 322 samples from patients undergoing long term treatment. Data have been grouped according to: age--3 to 6, 7 to 9, 10 to 14, and above 15 years old; number of drugs used in the treatment--mono- and polytherapy; dose--less than or equal to 10, 10.1 to 14.9, 15 to 19.9, and greater than or equal to 20 mg/kg; and plasma concentration found--less than 4, 4 to 8, 8.1 to 12, and greater than 12 mg/L. From the results it is concluded that the carbamazepine concentration-dose ratio increases with age in children, but is less than in adults, is higher in monotherapy than in polytherapy, and decreases as the dose increases.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3780114     DOI: 10.2165/00003088-198611050-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  9 in total

1.  Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy.

Authors:  J Christiansen; M Dam
Journal:  Acta Neurol Scand       Date:  1973       Impact factor: 3.209

Review 2.  Antiepileptic drugs and pregnancy: altered utilization patterns and teratogenesis.

Authors:  D Janz
Journal:  Epilepsia       Date:  1982       Impact factor: 5.864

Review 3.  Clinical pharmacokinetics of valproic acid.

Authors:  R Gugler; G E von Unruh
Journal:  Clin Pharmacokinet       Date:  1980 Jan-Feb       Impact factor: 6.447

4.  Carbamazepine plasma levels in children and adults: influence of age, dose, and associated therapy.

Authors:  D Battino; L Bossi; D Croci; S Franceschetti; C Gomeni; A Moise; A Vitali
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

5.  Variations in patients' compliance with doctors' orders: analysis of congruence between survey responses and results of empirical investigations.

Authors:  M S Davis
Journal:  J Med Educ       Date:  1966-11

6.  Carbamazepine in the treatment of partial epileptic seizures in infants and young children: a preliminary study.

Authors:  M Sillanpää; S Pynnönen; P Laippala; E Säkö
Journal:  Epilepsia       Date:  1979-10       Impact factor: 5.864

7.  Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique.

Authors:  L Bertilsson; B Höjer; G Tybring; J Osterloh; A Rane
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

Review 8.  Drug interactions with valproic acid.

Authors:  R H Levy; K M Koch
Journal:  Drugs       Date:  1982-12       Impact factor: 9.546

9.  Routine monitoring of carbamazepine and carbamazepine-10,11-epoxide in plasma by high-performance liquid chromatography using 10-methoxycarbamazepine as internal standard.

Authors:  A A Elyas; N Ratnaraj; V D Goldberg; P T Lascelles
Journal:  J Chromatogr       Date:  1982-08-13
  9 in total
  5 in total

Review 1.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

2.  Population pharmacokinetics of carbamazepine in Singapore epileptic patients.

Authors:  E Chan; H S Lee; S S Hue
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

3.  Carbamazepine clearance in paediatric epilepsy patients. Influence of body mass, dose, sex and co-medication.

Authors:  B Summers; R S Summers
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

Review 4.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.